Ori Wald
YOU?
Author Swipe
View article: Outcomes of Lobar and Sublobar Resection for Clinical Stage I Lung Neuroendocrine Tumors: An ENETS Center of Excellence Experience
Outcomes of Lobar and Sublobar Resection for Clinical Stage I Lung Neuroendocrine Tumors: An ENETS Center of Excellence Experience Open
Objectives: Lung neuroendocrine tumors (LNETs) are rare, comprising 1–2% of lung cancers. This study aimed to compare overall survival (OS) and recurrence-free survival (RFS) after lobar resection versus sublobar resection for LNETs and to…
View article: Development and characterisation of improved unifocal primary mouse lung cancer models with metastatic potential
Development and characterisation of improved unifocal primary mouse lung cancer models with metastatic potential Open
Lung cancer is the leading cause of cancer‐related death globally. To better understand the biology of lung cancer, mouse models have been developed using either tail vein‐injected tumour cell lines or genetically modified mice. The curren…
View article: Identification of Dinaciclib and Ganetespib as anti-inflammatory drugs using a novel HTP screening assay that targets IFNγ-dependent PD-L1
Identification of Dinaciclib and Ganetespib as anti-inflammatory drugs using a novel HTP screening assay that targets IFNγ-dependent PD-L1 Open
Introduction IFNγ plays both positive and negative roles in the regulation of innate and adaptive immune responses against tumors and virally infected tissues by upregulating CXCL10 and PD-L1 expression. Methods To identify novel pathways …
View article: Development and Application of Small Molecule–Peptide Conjugates as Cathepsin K-Specific Covalent Irreversible Inhibitors in Human Osteoclast and Lung Cancer
Development and Application of Small Molecule–Peptide Conjugates as Cathepsin K-Specific Covalent Irreversible Inhibitors in Human Osteoclast and Lung Cancer Open
Cathepsin K (CTSK), a proteolytic enzyme that degrades the extracellular matrix, is recognized as a significant therapeutic target for osteoporosis, osteoarthritis, and rheumatoid arthritis. Due to adverse effects, no clinically approved d…
View article: A Novel Cisplatin-Based Prodrug Inhibits Lysine Deacetylases, Suppresses Nucleotide Excision Repair, and Overcomes Resistance
A Novel Cisplatin-Based Prodrug Inhibits Lysine Deacetylases, Suppresses Nucleotide Excision Repair, and Overcomes Resistance Open
Cisplatin [cis-diamminedichloroplatinum(II)] is a widely used chemotherapeutic agent that induces cytotoxicity primarily through DNA damage, but drug resistance severely limits its efficacy and use. Cisplatin resistance is complex and mult…
View article: Enhancer landscape of lung neuroendocrine tumors reveals regulatory and developmental signatures with potential theranostic implications
Enhancer landscape of lung neuroendocrine tumors reveals regulatory and developmental signatures with potential theranostic implications Open
Well-differentiated low-grade lung neuroendocrine tumors (lung carcinoids or LNETs) are histopathologically classified as typical and atypical LNETs, but each subtype is still heterogeneous at both the molecular level and its clinical mani…
View article: Association of Concave Deformity of the Anterior Scalene on Magnetic Resonance Imaging with Vascular Variant of Neurogenic Thoracic Outlet Syndrome
Association of Concave Deformity of the Anterior Scalene on Magnetic Resonance Imaging with Vascular Variant of Neurogenic Thoracic Outlet Syndrome Open
Background: Neurogenic thoracic outlet syndrome (NTOS) is a dynamic compression of the brachial plexus. This study aimed to evaluate the correlation between the concave deformity of the posterior edge of the anterior scalene muscle (CDAS) …
View article: Development and Application of Reversible and Irreversible Covalent Probes for Human and Mouse Cathepsin‐K Activity Detection, Revealing Nuclear Activity (Adv. Sci. 38/2024)
Development and Application of Reversible and Irreversible Covalent Probes for Human and Mouse Cathepsin‐K Activity Detection, Revealing Nuclear Activity (Adv. Sci. 38/2024) Open
Activity‐Based Probes The cover highlights a novel chemical probe that binds a protease, cathepsin K (K), a key player in bone resorption. The probe detects active K in the cell by producing a fluorescent signal. In article number 2401518,…
View article: Development and Application of Reversible and Irreversible Covalent Probes for Human and Mouse Cathepsin‐K Activity Detection, Revealing Nuclear Activity
Development and Application of Reversible and Irreversible Covalent Probes for Human and Mouse Cathepsin‐K Activity Detection, Revealing Nuclear Activity Open
Cathepsin‐K (CTSK) is an osteoclast‐secreted cysteine protease that efficiently cleaves extracellular matrices and promotes bone homeostasis and remodeling, making it an excellent therapeutic target. Detection of CTSK activity in complex b…
View article: Particle uptake in cancer cells can predict malignancy and drug resistance using machine learning
Particle uptake in cancer cells can predict malignancy and drug resistance using machine learning Open
Tumor heterogeneity is a primary factor that contributes to treatment failure. Predictive tools, capable of classifying cancer cells based on their functions, may substantially enhance therapy and extend patient life span. The connection b…
View article: Outcomes of extracranial stereotactic body radiation therapy for induced oligometastatic non-small cell lung cancer on novel systemic therapy
Outcomes of extracranial stereotactic body radiation therapy for induced oligometastatic non-small cell lung cancer on novel systemic therapy Open
This study indicates that SBRT for OpersisD or OprogD in Stage IV NSCLC patients on osimertinib or ICIs is safe, very well tolerated, and may prolong the time before needing a shift in systemic therapy. Further prospective research is need…
View article: Enhancer landscape of lung neuroendocrine tumors reveals regulatory and developmental signatures with potential theranostic implications
Enhancer landscape of lung neuroendocrine tumors reveals regulatory and developmental signatures with potential theranostic implications Open
Well-differentiated low-grade lung neuroendocrine tumors (lung carcinoids or LNETs) are histopathologically classified as typical and atypical LNETs, but each subtype is still heterogeneous at both the molecular level and its clinical mani…
View article: Supplementary Figure 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i> Open
PDF - 90K, Demonstrates CXCR4 expression and function in K562 and K562LG-CXCR4 cells.
View article: Supplementary Table 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i> Open
PDF - 43K, Primer sequences.
View article: Supplementary Figure 2 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure 2 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i> Open
PDF - 32K, BKT140 structure.
View article: Supplementary Figure 2 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure 2 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i> Open
PDF - 32K, BKT140 structure.
View article: Data from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
Data from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i> Open
Functional role of CXCR4 in chronic myelogenous leukemia (CML) progression was evaluated. Elevated CXCR4 significantly increased the in vitro survival and proliferation in response to CXCL12. CXCR4 stimulation resulted in activation of ext…
View article: Data from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
Data from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i> Open
Functional role of CXCR4 in chronic myelogenous leukemia (CML) progression was evaluated. Elevated CXCR4 significantly increased the in vitro survival and proliferation in response to CXCL12. CXCR4 stimulation resulted in activation of ext…
View article: Supplementary Table 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Table 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i> Open
PDF - 43K, Primer sequences.
View article: Supplementary Figure 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i> Open
PDF - 90K, Demonstrates CXCR4 expression and function in K562 and K562LG-CXCR4 cells.
View article: Figure S2 from CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1–Mediated ERK and BCL2/Cyclin D1 Pathways
Figure S2 from CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1–Mediated ERK and BCL2/Cyclin D1 Pathways Open
miR-15a and miR-16-1 levels following transfection into NB cells
View article: Supplementary Figures and Tables from Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features
Supplementary Figures and Tables from Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features Open
Supplementary Figures and Tables
View article: Supplementary Figures and Tables from Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features
Supplementary Figures and Tables from Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features Open
Supplementary Figures and Tables
View article: Data from Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features
Data from Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features Open
Purpose: To reconcile the heterogeneity of thymic epithelial tumors (TET) and gain deeper understanding of the molecular determinants of TETs, we set out to establish a clinically relevant molecular classification system for these tumors.E…
View article: Data from CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1–Mediated ERK and BCL2/Cyclin D1 Pathways
Data from CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1–Mediated ERK and BCL2/Cyclin D1 Pathways Open
CXCR4 expression in neuroblastoma tumors correlates with disease severity. In this study, we describe mechanisms by which CXCR4 signaling controls neuroblastoma tumor growth and response to therapy. We found that overexpression of CXCR4 or…
View article: Figure S1 from CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1–Mediated ERK and BCL2/Cyclin D1 Pathways
Figure S1 from CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1–Mediated ERK and BCL2/Cyclin D1 Pathways Open
CXCL12 levels of NB cells
View article: Figure S3 from CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1–Mediated ERK and BCL2/Cyclin D1 Pathways
Figure S3 from CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1–Mediated ERK and BCL2/Cyclin D1 Pathways Open
miR-15a and miR-16-1 expression following antagomiR transfection
View article: Figure S3 from CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1–Mediated ERK and BCL2/Cyclin D1 Pathways
Figure S3 from CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1–Mediated ERK and BCL2/Cyclin D1 Pathways Open
miR-15a and miR-16-1 expression following antagomiR transfection